218153-08-3

Upstream product

• 584-08-7 potassium carbonate 
• 130311-75-0 6-(2-chlorophenyl)-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido<4',3':4,5>thieno<3,2-f><1,2,4>triazolo<4,3-a><1,4>diazepine 
• 218153-06-1 5-[1-(3-Methanesulfonyloxymethyl-phenyl)-1-pyridin-3-yl-meth-(E)-ylideneaminooxy]-pentanoic acid ethyl ester 
• 124038-07-9 3-bromo-O-(tert-butyldiphenylsilyl)benzyl ether 
• 500-22-1 3-pyridinecarboxaldehyde 

Downstream Products

• 218153-06-1 5-[1-(3-Methanesulfonyloxymethyl-phenyl)-1-pyridin-3-yl-meth-(E)-ylideneaminooxy]-pentanoic acid ethyl ester 
• 462656-34-4 5-[1-(3-Chloromethyl-phenyl)-1-pyridin-3-yl-meth-(E)-ylideneaminooxy]-pentanoic acid ethyl ester 

Relevant academic research and scientific papers

Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI)

Synthesis of carbamates 3b which possess dual-acting PAF antagonist/TxSI using unstable esters 1, diazepines 2, K2CO3 and 18-crown-6 is described.

Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs

A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxIs, such as Ridogrel (1).